When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
MTCR - Metacrine initiates mid-stage MET409 + empagliflozin study in diabetes and NASH
Metacrine Inc.
The first patient has been treated in Metacrine's (MTCR) Phase 2a trial evaluating MET409 (50 mg) in combination with empagliflozin (Jardiance), in patients with both type 2 diabetes mellitus (T2DM) and nonalcoholic steatohepatitis ((NASH)). The 12-week trial will enroll up to 120 patients in the U.S. Topline data are expected in H1 2022.